152 related articles for article (PubMed ID: 37751119)
1. B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study.
Nie Y; Li J; Wu D; Yang Y; Zhang L; Bai W; Jiang N; Qiao L; Huang C; Zhou S; Tian X; Li M; Zeng X; Peng L; Zhang W
Clin Exp Med; 2023 Dec; 23(8):4787-4795. PubMed ID: 37751119
[TBL] [Abstract][Full Text] [Related]
2. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
3. Identification of Covariates Modulating B-Cell Repopulation Kinetics in Subjects Receiving Rituximab Treatment.
Welte T; Westermann L; Kappes J; Schramm MA; Bemtgen X; Staudacher DL; Hug MJ; Venhoff N; Arnold F
Arthritis Rheumatol; 2023 Nov; 75(11):2045-2053. PubMed ID: 37276446
[TBL] [Abstract][Full Text] [Related]
4. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
Front Immunol; 2020; 11():566732. PubMed ID: 33384685
[TBL] [Abstract][Full Text] [Related]
5. Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function.
Mescia F; Salviani C; Tonoli M; Affatato S; Moratto D; Tedesco M; Guerini A; Gemmo A; Camoni M; Delbarba E; Zubani R; Garrafa E; Chiarini M; Gregorini G; Scolari F; Alberici F
Nephrol Dial Transplant; 2024 Mar; 39(4):683-693. PubMed ID: 37673675
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Springer JM; Funk RS
J Rheumatol; 2021 Nov; 48(11):1718-1724. PubMed ID: 34334366
[TBL] [Abstract][Full Text] [Related]
7. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
[TBL] [Abstract][Full Text] [Related]
8. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
Arnold J; Vital EM; Dass S; Aslam A; Rawstron AC; Savic S; Emery P; Md Yusof MY
Front Immunol; 2021; 12():803175. PubMed ID: 35095887
[TBL] [Abstract][Full Text] [Related]
9. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
[TBL] [Abstract][Full Text] [Related]
10. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
11. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
[TBL] [Abstract][Full Text] [Related]
12. Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Miyazaki Y; Nakayamada S; Kubo S; Ishikawa Y; Yoshikawa M; Sakata K; Iwata S; Miyagawa I; Nakano K; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):141. PubMed ID: 32539843
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
14. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.
Zonozi R; Cortazar FB; Jeyabalan A; Sauvage G; Nithagon P; Huizenga NR; Rosenthal JM; Sipilief A; Cosgrove K; Laliberte KA; Rhee EP; Pendergraft WF; Niles JL
Ann Rheum Dis; 2024 Feb; 83(3):351-359. PubMed ID: 38123922
[TBL] [Abstract][Full Text] [Related]
16. Low-dose rituximab as induction therapy for ANCA-associated vasculitis.
Takakuwa Y; Hanaoka H; Kiyokawa T; Iida H; Fujimoto H; Yamasaki Y; Yamada H; Kawahata K
Clin Rheumatol; 2019 Apr; 38(4):1217-1223. PubMed ID: 30680533
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
18. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
19. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
20. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
Md Yusof MY; Vital EM; Das S; Dass S; Arumugakani G; Savic S; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Sep; 74(9):1734-8. PubMed ID: 25854586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
